Seelos Therapeutics Closes Enrollment of Study for Intranasal Ketamine Treatment for Acute Suicidal Ideation and Behavior in Major Depressive Disorder Patients

Seelos Therapeutics has completed enrollment in its registration-directed study of SLS-002, an intranasal racemic ketamine for treating acute suicidal ideation and behavior (ASIB) in adults with major depressive disorder (MDD). The two-part clinical trial includes an open-label cohort followed by a randomized, double-blind, placebo-controlled study. Seelos aims to address the unmet need for ther..